Martínez-Raga Jose, Knecht Carlos, Cepeda Sonsoles
Departamento de Fisiología, Farmacología y Toxicología, Universidad CEU Cardenal Herrera, and Unidad de Conductas Adictivas Departamento de Salud de Gandía, Agencia Valenciana de Salut, Valencia, Spain.
Curr Drug Abuse Rev. 2008 Jun;1(2):213-21. doi: 10.2174/1874473710801020213.
Cocaine addiction is a chronic relapsing disorder associated with severe medical and psychosocial complications. However, there are no approved medications for cocaine dependent individuals. Modafinil, a medication that differs chemically and pharmacologically from other central nervous system stimulants, has been suggested to be potentially useful for this complex disorder. The present paper aims to critically review the published evidence from laboratory and clinical studies on modafinil for cocaine addiction, including discussion of its pharmacological characteristics and how it may relate with cocaine neurobiology. Whilst its exact mechanism of action remains to be elucidated, different neurotransmitter systems have been implicated, including modulation on dopamine, glutamate/GABA, noradrenaline and the hypocretin/orexin system, but it is possible that modafinil acts by a synergistic combination of mechanisms. With a favourable pharmacokinetic profile, it appears to have a low abuse potential. Laboratory and clinical studies provide consistent, albeit preliminary, evidence of the potential usefulness of modafinil for cocaine dependent patients. Not only there is no evidence of pharmacokinetic interactions between modafinil and cocaine, but in addition cocaine induced euphoria and cardiovascular effects appear to be attenuated by modafinil. Furthermore, modafinil has been shown to decrease cocaine self-administration. In addition, modafinil treated patient are more likely to achieve protracted abstinence than placebo treated patients. However, further research is needed to confirm these findings.
可卡因成瘾是一种慢性复发性疾病,伴有严重的医学和心理社会并发症。然而,目前尚无获批用于可卡因依赖者的药物。莫达非尼是一种在化学和药理学上与其他中枢神经系统兴奋剂不同的药物,已被认为可能对这种复杂疾病有用。本文旨在批判性地综述已发表的关于莫达非尼治疗可卡因成瘾的实验室和临床研究证据,包括讨论其药理学特性以及它与可卡因神经生物学的关系。虽然其确切作用机制仍有待阐明,但不同的神经递质系统已被牵涉其中,包括对多巴胺、谷氨酸/γ-氨基丁酸、去甲肾上腺素和下丘脑分泌素/食欲素系统的调节,但莫达非尼可能通过多种机制的协同作用发挥作用。因其具有良好的药代动力学特征,它似乎滥用潜力较低。实验室和临床研究提供了一致的、尽管是初步的证据,表明莫达非尼对可卡因依赖患者具有潜在的效用。不仅没有证据表明莫达非尼与可卡因之间存在药代动力学相互作用,而且莫达非尼似乎还能减轻可卡因引起的欣快感和心血管效应。此外,莫达非尼已被证明能减少可卡因的自我给药。此外,与接受安慰剂治疗的患者相比,接受莫达非尼治疗的患者更有可能实现长期戒断。然而,需要进一步的研究来证实这些发现。